Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

NCT06848920 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Differentiated Thyroid Carcinoma (DTC)
Neoadjuvant Therapy

Interventions

DRUG: Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment

Sponsor

Zhejiang University